[EN] BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER<br/>[FR] DÉRIVÉS BENZOXAZEPIN-4-(5H)-YLE ET LEUR UTILISATION POUR TRAITER LE CANCER
申请人:EXELIXIS INC
公开号:WO2010118208A1
公开(公告)日:2010-10-14
The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
这项发明涉及公式I的化合物及其药用可接受的盐或溶剂合物,以及制备和使用这些化合物的方法。
Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
申请人:Bradley Edward Stuart
公开号:US20050261272A1
公开(公告)日:2005-11-24
Compounds represented by Formula (I):
or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.
PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE
申请人:Bradley Edward Stuart
公开号:US20070244090A9
公开(公告)日:2007-10-18
Compounds represented by Formula (I):
or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.
The present invention provides 8-methyl-1-phenyl-imidazo[1,5-a]pyrazine deriva-tives according to formula I or pharmaceutically acceptable salts thereof. The compounds of the current invention show inhibitory activity against Lck and can be used for the treatment of Lck-mediated diseases or Lck-mediated conditions such as inflammatory disorders.
8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
申请人:de Man Adrianus Petrus Antonius
公开号:US08658794B2
公开(公告)日:2014-02-25
The present invention provides 8-methyl-1-phenyl-imidazo[1,5-a]pyrazine derivatives according to formula I or pharmaceutically acceptable salts thereof. The compounds of the current invention show inhibitory activity against Lck and can be used for the treatment of Lck-mediated diseases or Lck-mediated conditions such as inflammatory disorders.